Late-Breakers To Look Out For At ASCO 2020
Pfizer, Merck KGaA, Merck & Co, Amgen and AstraZeneca To Present
ASCO 2020, which takes place from 29-31 May, will necessarily depart from its predecessors in location, content and delivery. Here, with input from Biomedtracker and Datamonitor Healthcare, we take a look at what can be expected during this year’s late-breaking clinical trial sessions.
You may also be interested in...
Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.
Proving a survival benefit in the head-to-head ENDEAVOR relapsed multiple myeloma study gives Amgen's Kyprolis a leg up ahead of the entry of Velcade generics in the US this year.
Because CLARION was designed to test Kyprolis head-to-head against fellow proteasome inhibitor Velcade, the failure could hurt the drug's standing in its class. But the trial design used a regimen largely phased out of clinical practice and Amgen has other chances to prove superiority.